Medtronic’s MiniMed 780G System Receives the US FDA’s Approval for the Treatment of Type 1 Diabetes
- The US FDA has approved the MiniMed 780G system with the Guardian 4 sensor. The system features SmartGuard technology that automatically adjusts insulin delivery & corrects glucose levels every 5 minutes, 24/7 with no finger pricks for basal & bolus insulin needs
- The system also offers multiple glucose targets as compared to a single target. In a pivotal trial, use of the MiniMed 780G System was associated with a time in the range of 70-180 mg/dL of 75% & an overall time below the range of 1.8%
- In the ADAPT study, MiniMed780G System users experienced a 27.6% increase in time in range and a 1.4% reduction in mean HbA1C over those using multiple daily injections in conjunction with an intermittently scanned CGM without increased time in hypoglycemia
Ref: PR Newswire | Image: Medtronic
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.